{"transactions":[{"id":907458,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-12T16:34:07.000Z","date":"2026-02-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":6277,"price":12.82,"value":80471.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation."}],"balance_after":373315,"source":{"system":"sec-edgar","filing":"0001193125-26-048867","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000119312526048867/ownership.xml","form_type":"4"}},{"id":907457,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-12T16:34:07.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":12362,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued upon vesting of performance stock units granted to the reporting person on April 3, 2025 based on the achievement of performance criteria determined to be satisfied on February 10, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,410 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2026."}],"balance_after":379592,"source":{"system":"sec-edgar","filing":"0001193125-26-048867","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000119312526048867/ownership.xml","form_type":"4"}},{"id":955092,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-02T17:46:12.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":226156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the total number of shares of common stock subject to the option vest monthly following the Vesting Commencement Date, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":221156,"derivative":{"exercise_price":15.71,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":226156},"source":{"system":"sec-edgar","filing":"0001193125-26-001127","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000119312526001127/ownership.xml","form_type":"4"}},{"id":955091,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-02T17:46:12.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":251034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted on January 2, 2026. 1/3 of the total number of RSUs granted vest on each of the first three anniversaries of January 2, 2026, the vesting commencement date (the \"Vesting Commencement Date\"), subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":364820,"source":{"system":"sec-edgar","filing":"0001193125-26-001127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000119312526001127/ownership.xml","form_type":"4"}},{"id":961949,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-19T17:45:41.000Z","date":"2025-12-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":31502,"price":15.36,"value":483870.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation."}],"balance_after":113786,"source":{"system":"sec-edgar","filing":"0001193125-25-327126","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000119312525327126/ownership.xml","form_type":"4"}},{"id":961948,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-19T17:45:41.000Z","date":"2025-12-17","kind":"grant","planned":false,"acquired":true,"shares":62038,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued upon vesting of performance stock units granted to the reporting person on April 3, 2025 based on the achievement of performance criteria determined to be satisfied on December 17, 2025."}],"balance_after":145288,"source":{"system":"sec-edgar","filing":"0001193125-25-327126","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000119312525327126/ownership.xml","form_type":"4"}},{"id":969240,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-15T16:15:08.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2026, subject to the Reporting Person's continuous service through such date."}],"balance_after":20000,"derivative":{"exercise_price":0.3756,"expiration_date":"2035-12-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001417397-25-000004","document":"form4-12152025_041203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000141739725000004/form4-12152025_041203.xml","form_type":"4"}},{"id":983456,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Performance Shares","published_at":"2025-12-02T18:45:22.000Z","date":"2025-11-28","kind":"exercise","planned":false,"acquired":false,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On April 3, 2025, the reporting person was granted 360,000 performance stock units, of which 90,000 vested on September 25, 2025 and an additional 90,000 vested on November 28, 2025, in each case due to the achievement of the applicable stock price hurdle. The remaining performance stock units will vest based on the achievement of stock price hurdles over a period of four years following the grant date, subject to the reporting person's continued service through the date each such stock price hurdle is achieved."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On April 3, 2025, the reporting person was granted 360,000 performance stock units, of which 90,000 vested on September 25, 2025 and an additional 90,000 vested on November 28, 2025, in each case due to the achievement of the applicable stock price hurdle. The remaining performance stock units will vest based on the achievement of stock price hurdles over a period of four years following the grant date, subject to the reporting person's continued service through the date each such stock price hurdle is achieved."}],"balance_after":180000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001193125-25-305575","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000119312525305575/ownership.xml","form_type":"4"}},{"id":983455,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-02T18:45:22.000Z","date":"2025-11-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":48375,"price":15.62,"value":755617.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation."}],"balance_after":83250,"source":{"system":"sec-edgar","filing":"0001193125-25-305575","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000119312525305575/ownership.xml","form_type":"4"}},{"id":983454,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-02T18:45:22.000Z","date":"2025-11-28","kind":"exercise","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":131625,"source":{"system":"sec-edgar","filing":"0001193125-25-305575","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000119312525305575/ownership.xml","form_type":"4"}},{"id":1031706,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Performance Shares","published_at":"2025-09-26T19:03:39.000Z","date":"2025-09-25","kind":"exercise","planned":false,"acquired":false,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On April 3, 2025, the reporting person was granted 360,000 performance stock units, of which 90,000 vested on September 25, 2025 due to the achievement of the applicable stock price hurdle. The remaining performance stock units will vest based on the achievement of stock price hurdles over a period of four years following the grant date, subject to the reporting person's continued service through the date each such stock price hurdle is achieved."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On April 3, 2025, the reporting person was granted 360,000 performance stock units, of which 90,000 vested on September 25, 2025 due to the achievement of the applicable stock price hurdle. The remaining performance stock units will vest based on the achievement of stock price hurdles over a period of four years following the grant date, subject to the reporting person's continued service through the date each such stock price hurdle is achieved."}],"balance_after":270000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001193125-25-220950","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000119312525220950/ownership.xml","form_type":"4"}},{"id":1031705,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-26T19:03:39.000Z","date":"2025-09-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":48375,"price":11.66,"value":564052.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation."}],"balance_after":41625,"source":{"system":"sec-edgar","filing":"0001193125-25-220950","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000119312525220950/ownership.xml","form_type":"4"}},{"id":1031704,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-26T19:03:39.000Z","date":"2025-09-25","kind":"exercise","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":90000,"source":{"system":"sec-edgar","filing":"0001193125-25-220950","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000119312525220950/ownership.xml","form_type":"4"}},{"id":1179300,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-03T17:30:02.000Z","date":"2025-04-03","kind":"grant","planned":false,"acquired":true,"shares":1085000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option will vest with respect to 25% of the shares of common stock on April 3, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates."}],"balance_after":1085000,"derivative":{"exercise_price":5.01,"expiration_date":"2035-04-02","underlying":"Common Stock","underlying_shares":1085000},"source":{"system":"sec-edgar","filing":"0000950170-25-050621","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000095017025050621/ownership.xml","form_type":"4"}},{"id":1179299,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Performance Shares","published_at":"2025-04-03T17:30:02.000Z","date":"2025-04-03","kind":"grant","planned":false,"acquired":true,"shares":360000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The performance stock units will vest based on the achievement of stock price hurdles and service-based vesting requirements over a period of four years following the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The performance stock units will vest based on the achievement of stock price hurdles and service-based vesting requirements over a period of four years following the grant date."}],"balance_after":360000,"derivative":{"underlying":"Common Stock","underlying_shares":360000},"source":{"system":"sec-edgar","filing":"0000950170-25-050621","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000095017025050621/ownership.xml","form_type":"4"}},{"id":1332196,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-13T16:15:26.000Z","date":"2024-12-12","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2025, subject to the Reporting Person's continuous service through such date."}],"balance_after":20000,"derivative":{"exercise_price":2.4,"expiration_date":"2034-12-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-24-029288","document":"form4-12132024_041211.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000141588924029288/form4-12132024_041211.xml","form_type":"4"}},{"id":1691869,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-03T17:10:38.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest on January 1, 2025, subject to the Reporting Person's continuous service through such date."}],"balance_after":20000,"derivative":{"exercise_price":2.33,"expiration_date":"2033-12-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-24-000460","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000120919124000460/doc4.xml","form_type":"4"}},{"id":1709080,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-12-15T17:02:37.000Z","date":"2023-12-13","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. These options vest on December 13, 2024, subject to the Reporting Person's continuous service through such date."}],"balance_after":20000,"derivative":{"exercise_price":2.7,"expiration_date":"2033-12-12","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-058809","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000120919123058809/doc4.xml","form_type":"4"}},{"id":2064190,"issuer":{"id":11899,"kind":"organization","name":"VIVEVE MEDICAL, INC.","symbol":"VIVE"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2023-01-05T16:04:01.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":72000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest in full on the earlier of December 1, 2023 or the closing of a Sale Event (as defined in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan), subject to the reporting person's continuous service to the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest in full on the earlier of December 1, 2023 or the closing of a Sale Event (as defined in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan), subject to the reporting person's continuous service to the Issuer."}],"balance_after":72000,"derivative":{"underlying":"Common Stock","underlying_shares":72000},"source":{"system":"sec-edgar","filing":"0001437749-23-000485","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879682/000143774923000485/rdgdoc.xml","form_type":"4"}},{"id":2186861,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2022-08-12T17:10:53.000Z","date":"2022-08-10","kind":"grant","acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the annual award to non-executive directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. These options vest over a 12-month period in equal, monthly installments, ending August 10, 2023."}],"balance_after":20500,"derivative":{"exercise_price":0.312,"expiration_date":"2032-08-10","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001209191-22-045649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000120919122045649/doc4.xml","form_type":"4"}},{"id":2442164,"issuer":{"id":11899,"kind":"organization","name":"VIVEVE MEDICAL, INC.","symbol":"VIVE"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Purchase)","published_at":"2022-01-06T16:02:55.000Z","date":"2022-01-04","kind":"grant","acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan, as amended (the \"2013 Plan\") and received 48,000 non-qualified stock options on January 4, 2022 (the \"Grant Date\"). The non-qualified stock options shall vest and become exercisable in 48 equal monthly installments from the Grant Date."}],"balance_after":48000,"derivative":{"exercise_price":1.26,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001437749-22-000544","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879682/000143774922000544/rdgdoc.xml","form_type":"4"}},{"id":2468635,"issuer":{"id":11899,"kind":"organization","name":"VIVEVE MEDICAL, INC.","symbol":"VIVE"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-12-17T16:03:05.000Z","date":"2021-12-15","kind":"disposition_to_issuer","acquired":false,"shares":28,"price":1.41,"value":39.48,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.415 to $1.4001. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":25,"source":{"system":"sec-edgar","filing":"0001437749-21-028891","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879682/000143774921028891/rdgdoc.xml","form_type":"4"}},{"id":2629153,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-07-20T17:04:39.000Z","date":"2021-07-19","kind":"grant","acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest over a 12 month period in equal, monthly installments, ending July 19, 2022."}],"balance_after":20500,"derivative":{"exercise_price":2.75,"expiration_date":"2031-07-19","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001209191-21-047406","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000120919121047406/doc4.xml","form_type":"4"}},{"id":2655263,"issuer":{"id":11899,"kind":"organization","name":"VIVEVE MEDICAL, INC.","symbol":"VIVE"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Purchase)","published_at":"2021-06-25T16:07:28.000Z","date":"2021-06-23","kind":"grant","acquired":true,"shares":116200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the \"Plan\") and received 116,200 non-qualified stock options on June 23, 2021 (the \"Grant Date\"). The non-qualified stock options shall vest and become exercisable in 48 equal monthly installments from the Grant Date."}],"balance_after":116200,"derivative":{"exercise_price":2.73,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":116200},"source":{"system":"sec-edgar","filing":"0001437749-21-015660","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879682/000143774921015660/rdgdoc.xml","form_type":"4"}},{"id":2899830,"issuer":{"id":11899,"kind":"organization","name":"VIVEVE MEDICAL, INC.","symbol":"VIVE"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2021-01-22T19:15:58.000Z","date":"2021-01-20","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan and received 50,000 RSUs on January 20, 2021 (the \"Grant Date\"). The RSUs vest in full on the second anniversary of the Grant Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan and received 50,000 RSUs on January 20, 2021 (the \"Grant Date\"). The RSUs vest in full on the second anniversary of the Grant Date."}],"balance_after":50000,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001437749-21-001108","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879682/000143774921001108/rdgdoc.xml","form_type":"4"}},{"id":3025438,"issuer":{"id":11899,"kind":"organization","name":"VIVEVE MEDICAL, INC.","symbol":"VIVE"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Purchase)","published_at":"2020-09-22T11:04:15.000Z","date":"2020-09-21","kind":"grant","acquired":true,"shares":165000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the \"Plan\") and received 165,000 non-qualified stock options on September 21, 2020 (the \"Grant Date\"). The non-qualified stock options shall vest in full on the first anniversary of the Grant Date."}],"balance_after":165000,"derivative":{"exercise_price":0.5397,"expiration_date":"2030-09-20","underlying":"Common Stock","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001437749-20-019986","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879682/000143774920019986/rdgdoc.xml","form_type":"4"}},{"id":3067251,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2020-08-05T16:38:13.000Z","date":"2020-08-03","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest over a 12 month period in equal, quarterly installments, ending August 3, 2021."}],"balance_after":22500,"derivative":{"exercise_price":1.72,"expiration_date":"2030-08-03","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001209191-20-045129","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000120919120045129/doc4.xml","form_type":"4"}},{"id":3180578,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-07T17:19:51.000Z","date":"2020-04-03","kind":"grant","acquired":true,"shares":14499,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. (\"Menlo\") issued additional shares of its common stock pursuant to certain contingent stock rights (\"CSRs\") issued in connection with the March 9, 2020 merger (the \"Merger\") of Menlo and Foamix Pharmaceuticals Ltd. (\"Foamix\"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the \"Final Exchange Ratio\"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares."}],"balance_after":536537,"source":{"system":"sec-edgar","filing":"0001209191-20-023799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000120919120023799/doc4.xml","form_type":"4"}},{"id":3197840,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-03-23T16:44:05.000Z","date":"2020-03-19","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest and become exercisable as to 1/3rd of the shares subject to the option on each annual anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":45000,"derivative":{"exercise_price":2.67,"expiration_date":"2030-03-19","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-20-020657","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000120919120020657/doc4.xml","form_type":"4"}},{"id":3215603,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-11T17:55:09.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":7108,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in the merger of Foamix Pharmaceuticals Ltd. (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for 12,000 Foamix ordinary shares. The closing price of a Foamix ordinary share on March 6, 2020, the last trading day before such merger, was $2.99. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, which may entitle the Reporting Person to certain additional Menlo equity securities as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,166 shares of Menlo common stock acquired pursuant to the Menlo Therapeutics Inc. Employee Stock Purchase Plan and Rule 16b-3(c)."}],"balance_after":522038,"source":{"system":"sec-edgar","filing":"0001209191-20-018221","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000120919120018221/doc4.xml","form_type":"4"}},{"id":3340821,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-12-16T17:11:35.000Z","date":"2019-12-11","kind":"exercise","acquired":false,"shares":14000,"price":1.83,"value":25620.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Non-Qualified Stock Option was exercised and the shares were acquired in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code."}],"balance_after":357641,"derivative":{"exercise_date":"2016-11-30","expiration_date":"2026-02-02","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0000899243-19-029290","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000089924319029290/doc4a.xml","form_type":"4/A","original_submission_date":"2019-12-13"}},{"id":3340820,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2019-12-16T17:11:35.000Z","date":"2019-12-11","kind":"exercise","acquired":false,"shares":238800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 29, 2019, the Reporting Person was granted 238,800 restricted stock units (\"RSUs\"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 29, 2019, the Reporting Person was granted 238,800 restricted stock units (\"RSUs\"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 29, 2019, the Reporting Person was granted 238,800 restricted stock units (\"RSUs\"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":238800},"source":{"system":"sec-edgar","filing":"0000899243-19-029290","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000089924319029290/doc4a.xml","form_type":"4/A","original_submission_date":"2019-12-13"}},{"id":3340819,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2019-12-16T17:11:35.000Z","date":"2019-12-11","kind":"exercise","acquired":true,"shares":14000,"price":1.83,"value":25620.0,"ownership":{"direct":true},"balance_after":509764,"source":{"system":"sec-edgar","filing":"0000899243-19-029290","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000089924319029290/doc4a.xml","form_type":"4/A","original_submission_date":"2019-12-13"}},{"id":3340818,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2019-12-16T17:11:35.000Z","date":"2019-12-11","kind":"tax_withholding","acquired":false,"shares":85210,"price":4.52,"value":385149.2,"ownership":{"direct":true},"balance_after":495764,"source":{"system":"sec-edgar","filing":"0000899243-19-029290","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000089924319029290/doc4a.xml","form_type":"4/A","original_submission_date":"2019-12-13"}},{"id":3340817,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2019-12-16T17:11:35.000Z","date":"2019-12-11","kind":"exercise","acquired":true,"shares":238800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 29, 2019, the Reporting Person was granted 238,800 restricted stock units (\"RSUs\"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes the acquisition of 6,234 shares of the Issuer's common stock pursuant to the Menlo Therapeutics Inc. Employee Stock Purchase Plan (\"ESPP\") for the ESPP purchase periods of September 1, 2018 through February 28, 2019 and March 1, 2019 through August 31, 2019. This transaction is exempt under Rule 16b-3(c)."}],"balance_after":580974,"source":{"system":"sec-edgar","filing":"0000899243-19-029290","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000089924319029290/doc4a.xml","form_type":"4/A","original_submission_date":"2019-12-13"}},{"id":3342258,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-12-13T21:54:23.000Z","date":"2019-12-11","kind":"exercise","acquired":false,"shares":14000,"price":1.83,"value":25620.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Non-Qualified Stock Option was exercised and the shares were acquired in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code."}],"balance_after":357641,"derivative":{"exercise_date":"2016-11-30","expiration_date":"2026-02-02","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0000899243-19-029185","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000089924319029185/doc4.xml","form_type":"4"}},{"id":3342257,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2019-12-13T21:54:23.000Z","date":"2019-12-11","kind":"exercise","acquired":false,"shares":238800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 29, 2019, the Reporting Person was granted 238,800 restricted stock units (\"RSUs\"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 29, 2019, the Reporting Person was granted 238,800 restricted stock units (\"RSUs\"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 29, 2019, the Reporting Person was granted 238,800 restricted stock units (\"RSUs\"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":238800},"source":{"system":"sec-edgar","filing":"0000899243-19-029185","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000089924319029185/doc4.xml","form_type":"4"}},{"id":3342256,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2019-12-13T21:54:23.000Z","date":"2019-12-11","kind":"exercise","acquired":true,"shares":14000,"price":1.83,"value":25620.0,"ownership":{"direct":true},"balance_after":509764,"source":{"system":"sec-edgar","filing":"0000899243-19-029185","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000089924319029185/doc4.xml","form_type":"4"}},{"id":3342255,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2019-12-13T21:54:23.000Z","date":"2019-12-11","kind":"tax_withholding","acquired":false,"shares":85210,"price":4.52,"value":385149.2,"ownership":{"direct":true},"balance_after":495764,"source":{"system":"sec-edgar","filing":"0000899243-19-029185","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000089924319029185/doc4.xml","form_type":"4"}},{"id":3342254,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2019-12-13T21:54:23.000Z","date":"2019-12-11","kind":"exercise","acquired":true,"shares":238800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 29, 2019, the Reporting Person was granted 238,800 restricted stock units (\"RSUs\"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes the acquisition of 6,234 shares of the Issuer's common stock pursuant to the Menlo Therapeutics Inc. Employee Stock Purchase Plan (\"ESPP\") for the ESPP purchase periods of September 1, 2018 through February 28, 2019 and March 1, 2019 through August 31, 2019, which shares were acquired in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. This transaction is exempt under Rule 16b-3(c)."}],"balance_after":580974,"source":{"system":"sec-edgar","filing":"0000899243-19-029185","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000089924319029185/doc4.xml","form_type":"4"}},{"id":3358055,"issuer":{"id":11899,"kind":"organization","name":"VIVEVE MEDICAL, INC.","symbol":"VIVE"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2019-11-27T19:29:09.000Z","date":"2019-11-26","kind":"grant","acquired":true,"shares":660000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest and become exercisable in 48 equal monthly installments after November 26, 2019, subject to the Reporting Person's continuous service to the Issuer through each such date."}],"balance_after":660000,"derivative":{"exercise_price":0.869,"expiration_date":"2029-11-25","underlying":"Common Stock","underlying_shares":660000},"source":{"system":"sec-edgar","filing":"0001437749-19-023669","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879682/000143774919023669/rdgdoc.xml","form_type":"4"}},{"id":3444482,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2019-08-07T19:30:03.000Z","date":"2019-07-29","kind":"grant","acquired":true,"shares":238800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive a share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs shall vest in two (2) equal annual installments beginning July 29, 2020, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissable Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Not Applicable"}],"balance_after":1050100,"derivative":{"underlying":"Common Stock","underlying_shares":238800},"source":{"system":"sec-edgar","filing":"0000899243-19-021299","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000089924319021299/doc4a.xml","form_type":"4/A","original_submission_date":"2019-07-31"}},{"id":3451936,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2019-07-31T18:35:56.000Z","date":"2019-07-29","kind":"grant","acquired":true,"shares":238800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive a share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs shall vest in two (2) equal annual installments beginning July 29, 2020, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Not Applicable"}],"balance_after":1050100,"derivative":{"underlying":"Common Stock","underlying_shares":238800},"source":{"system":"sec-edgar","filing":"0000899243-19-020704","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000089924319020704/doc4.xml","form_type":"4"}},{"id":3506761,"issuer":{"id":11899,"kind":"organization","name":"VIVEVE MEDICAL, INC.","symbol":"VIVE"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Purchase)","published_at":"2019-05-31T16:31:02.000Z","date":"2019-05-29","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the \"Plan\") and received 35,000 non-qualified stock options on May 29, 2019 (the \"Grant Date\"). The non-qualified stock options shall vest in full on the first anniversary of the Grant Date."}],"balance_after":35000,"derivative":{"exercise_price":0.58,"expiration_date":"2029-05-28","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001437749-19-011163","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879682/000143774919011163/rdgdoc.xml","form_type":"4"}},{"id":3566623,"issuer":{"id":11899,"kind":"organization","name":"VIVEVE MEDICAL, INC.","symbol":"VIVE"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-04-03T16:34:37.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":24199,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the \"Plan\") and received a restricted stock award of 24,199 shares of common stock on April 1, 2019 (the \"Grant Date\").  The restricted stock award shall vest in full on the Grant Date."}],"balance_after":24199,"source":{"system":"sec-edgar","filing":"0001437749-19-006478","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879682/000143774919006478/rdgdoc.xml","form_type":"4"}},{"id":3694960,"issuer":{"id":11899,"kind":"organization","name":"VIVEVE MEDICAL, INC.","symbol":"VIVE"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Purchase)","published_at":"2019-01-16T17:07:59.000Z","date":"2019-01-15","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the \"Plan\") and received 35,000 non-qualified stock options on January 15, 2019 (the \"Grant Date\"). The non-qualified stock options shall vest in full on the first anniversary of the Grant Date."}],"balance_after":35000,"derivative":{"exercise_price":1.24,"expiration_date":"2029-01-14","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001437749-19-000932","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879682/000143774919000932/rdgdoc.xml","form_type":"4"}},{"id":3733923,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2018-12-12T18:42:30.000Z","date":"2018-12-10","kind":"grant","acquired":true,"shares":141900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest over a period of four years, with 1/48th of the shares subject to the option vesting monthly."}],"balance_after":141900,"derivative":{"exercise_price":5.51,"expiration_date":"2028-12-10","underlying":"Common Stock","underlying_shares":141900},"source":{"system":"sec-edgar","filing":"0001566044-18-000011","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000156604418000011/edgardoc.xml","form_type":"4"}},{"id":3816308,"issuer":{"id":11899,"kind":"organization","name":"VIVEVE MEDICAL, INC.","symbol":"VIVE"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true}}],"security":"Non-Qualified Stock Options","published_at":"2018-09-14T14:08:18.000Z","date":"2018-09-13","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan and received 70,000 non-qualified stock options on September 13, 2018 (the \"Grant Date\"). The non-qualified stock options will vest in equal annual installments over three years beginning on the first anniversary of the Grant Date."}],"balance_after":70000,"derivative":{"exercise_price":3.45,"expiration_date":"2028-09-12","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001437749-18-017040","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879682/000143774918017040/rdgdoc.xml","form_type":"4"}},{"id":3945482,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2018-05-04T16:31:55.000Z","date":"2018-05-03","kind":"grant","acquired":true,"shares":212850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest over a period of four years, with 1/48th of the shares subject to the option vesting monthly."}],"balance_after":669400,"derivative":{"exercise_price":8.49,"expiration_date":"2028-05-02","underlying":"Common Stock","underlying_shares":212850},"source":{"system":"sec-edgar","filing":"0001209191-18-028118","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000120919118028118/doc4.xml","form_type":"4"}},{"id":4544875,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-11-22T16:14:38.000Z","date":"2016-11-21","kind":"exercise","acquired":true,"shares":1125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. (\"KalVista\"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the \"Transaction\"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":7.84,"expiration_date":"2023-06-06","underlying":"Common Stock","underlying_shares":1125},"source":{"system":"sec-edgar","filing":"0001140361-16-087582","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000114036116087582/doc1.xml","form_type":"4"}},{"id":4544874,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-11-22T16:14:38.000Z","date":"2016-11-21","kind":"other","acquired":false,"shares":99,"price":8.5932,"value":850.7268,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. (\"KalVista\"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the \"Transaction\"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-16-087582","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000114036116087582/doc1.xml","form_type":"4"}},{"id":4544873,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-11-22T16:14:38.000Z","date":"2016-11-21","kind":"tax_withholding","acquired":false,"shares":1026,"price":8.5932,"value":8816.6232,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. (\"KalVista\"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the \"Transaction\"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction."}],"balance_after":99,"source":{"system":"sec-edgar","filing":"0001140361-16-087582","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000114036116087582/doc1.xml","form_type":"4"}},{"id":4544872,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":66703,"kind":"person","name":"Basta Steven L","position":1,"cik":"0001417397","reported_name":"Basta Steven L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-11-22T16:14:38.000Z","date":"2016-11-21","kind":"exercise","acquired":true,"shares":1125,"price":7.84,"value":8820.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. (\"KalVista\"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the \"Transaction\"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction."}],"balance_after":1125,"source":{"system":"sec-edgar","filing":"0001140361-16-087582","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417397/000114036116087582/doc1.xml","form_type":"4"}}]}